Xpert® vanA/vanB
Rapid VRE screening for active outbreak prevention and control in around 48 minutes
Sign in or create a MyCepheid account to add items to cart
Test pack size(s)
product image
10 Tests
GXVANA/B-CE-10
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
Collection devices
product image
Collection Device (Pack of 50)
900-0370
Qty
Unit price
Subtotal
USD
Product is not available for purchase in your region.
Total
{{currency}}
0
Error adding items to cart. If this error persists, please contact Digital Support

The Need

VRE: A growing concern
The rapid and continuous increase in the percentage of VRE carriage in the EU/EEA is a cause for concern.2
  • Infections and deaths attributable to VRE almost doubled between 2007-20152
  • The population-weighted mean percentage for VRE increased from 10.5% in 2015 to 17.3% in 20182
  • High resistance levels have been reported from all regions in Europe2
  • VRE has a significant impact on patient length of stay, and in turn, hospitalization costs3
(2) ECDC Surveillance Report. Surveillance of antimicrobial resistance in Europe 2018. Accessed Jun 2021. https://www.ecdc.europa.eu/en/publications-data/surveillance-antimicrobial-resistance-europe-2018
(3) Hemapanpairoa J, et al. Does vancomycin resistance increase mortality? Clinical outcomes and predictive factors for mortality in patients with Enterococcus faecium infections. Antibiotics. 2021 Jan;10(2):105.
(4) Saliba R, et al. Can real-time polymerase chain reaction allow a faster recovery of hospital activity in cases of an incidental discovery of carbapenemase-producing Enterobacteriaceae and vancomycin-resistant enterococci carriers? J Hosp Infect. 2019 Oct;103(2).

The Solution

VRE has become a substantive and growing burden in hospitalised patients, prompting the need for earlier and accurate detection.
Xpert vanA/vanB enables:
  • Fast identification of VRE in around 45 minutes
  • Laboratory efficiencies with on-demand workflows requiring minimal hands-on time, 24/7
  • Timely infection control measures to reduce transmission and outbreaks, and enable appropriate use of isolation facilities
(1) Birgand G, et al. Rapid detection of glycopeptide-resistant enterococci: impact on decision-making and costs. Antimicrob Rest Infec Control. 2013 Nov;2(30).

The Impact

Fast and accurate PCR testing with Xpert®vanA/vanB greatly improves time to result, allowing healthcare professionals to quickly and appropriately manage patients, reducing transmission and enabling more efficient bed management.4
Optimize Workflow and Patient Management
  • Deliver actionable results to clinicians and infection control teams in around 45 minutes
  • On-demand STAT testing provides results 24/7
  • Ease of use and minimal hands-on-time enables more efficient use of staff time
(4) Saliba R, et al. Can real-time polymerase chain reaction allow a faster recovery of hospital activity in cases of an incidental discovery of carbapenemase-producing Enterobacteriaceae and vancomycin-resistant enterococci carriers? J Hosp Infect. 2019 Oct;103(2).

Product Resources

Product Information